Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Lipocalin-type prostaglandin d2 synthase production accelerating agent

A technology of lipocalin and prostaglandin, which can be used in drug combination, biological testing, biological material analysis, etc., and can solve problems such as unknown promotion effect.

Pending Publication Date: 2020-08-07
HYOGO COLLEGE OF MEDICINE +1
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, as the action and effect of this extract on the brain, it is known that it has a therapeutic effect on ischemic diseases such as cerebral infarction (Japanese Patent Laid-Open No. 2000-16942) and a production-promoting action of neurotrophic factors such as BDNF (International Publication WO2011 / 162317 bulletin), but it is unknown so far that this extract has the effect of promoting the production of L-PGDS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipocalin-type prostaglandin d2 synthase production accelerating agent
  • Lipocalin-type prostaglandin d2 synthase production accelerating agent
  • Lipocalin-type prostaglandin d2 synthase production accelerating agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0102] Embodiment 1 The manufacture of this extract

[0103]The vaccinia virus was inoculated intradermally in the skin of healthy mature rabbits, and the pockmarked skin was excised and harvested. After cleaning and disinfecting the collected skin with phenol solution, remove the excess phenol solution, crush it, add the phenol solution to mix, let it stand for 3-7 days, and then stir for 3-4 days while heating to 35-40°C. Then, the extract liquid obtained by solid-liquid separation was adjusted to pH 4.5-5.2 with hydrochloric acid, and after heat treatment at 90-100° C. for 30 minutes, protein was removed by filtration. Then the filtrate was adjusted to pH 9.0-9.5 with sodium hydroxide, heat-treated at 90-100° C. for 15 minutes, and then solid-liquid separation was performed.

[0104] The obtained protein-removing solution was adjusted to pH 4.0-4.3 with hydrochloric acid, 2% of the mass of the protein-removing solution was added with activated carbon, stirred for 2 hours, ...

Embodiment 2

[0105] Embodiment 2 pharmacological test

[0106] Next, the method and results of the pharmacological test on the L-PGDS production-promoting effect using the present extract obtained in Example 1 above as the test substance are shown. In addition, in the following pharmacological test, regarding the introduction of cerebral infarction into C.B-17 mice and the isolation and culture of iSCs from the cerebral infarction focus, according to Nakagomi, T. et al. Eur. J. Neurosci., 29, 1842_1852 , carried out by the method described in 2009.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a lipocalin-type prostaglandin D2 synthase (L-PGDS) production accelerating agent, more specifically, an L-PGDS production accelerating agent in pericytes or ischemia-induced multipotent stem cells (iSC) de-differentiated from pericytes. The present invention has verified that a substance having an L-PGDS production accelerating effect is contained in an extract of inflammatory tissues inoculated with vaccinia virus. The L-PGDS production accelerating agent according to the present invention is highly useful as a drug or the like for prevention, treatment, or relapse prevention of disorders on which the enhanced expression of L-PGDS is expected to be effective, more specifically, cerebral vascular disorders such as brain infarction, dementia such as Alzheimer's disease, or sleep disorder.

Description

technical field [0001] The present invention relates to lipocalin-type prostaglandin D2 synthetase (hereinafter, sometimes referred to as "L-PGDS". In addition, the enzyme called "lipocalin-type prostaglandin D2 synthase" may include In the present invention.) production accelerators and the like. Background technique [0002] Prostaglandin D2 synthase (PGDS) is known to have a lipocalin type (L-) PGDS distributed in the central nervous system, male reproductive organs, heart, etc., and a hematopoietic type (H-) distributed in mast cells and Th2 cells. ) 2 types of PGDS. L-PGDS has an activity of catalyzing the isomerization reaction from prostaglandin H2 (PGH2), which is a common intermediate in prostaglandin biosynthesis, to prostaglandin D2 (PGD2). On the other hand, L-PGDS structurally belongs to the lipocalin family that functions as a carrier of fat-soluble substances. Therefore, L-PGDS is a multifunctional protein with two faces of PGD2 biosynthetic enzyme and lipo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K35/36A61P9/10A61P25/20A61P25/28A61P43/00C12Q1/6844G01N33/15G01N33/50
CPCA61K35/36A61K35/76A61P9/10A61P25/00A61P25/28A61P25/20G01N2333/99G01N33/5073G01N2800/2814G01N2800/2864G01N2800/2871G01N2333/07A61K35/44A61K45/06C12Q1/6844G01N2500/00C12Q2600/136A61K9/0053G01N33/15G01N33/50
Inventor 松山知弘中込隆之福田有
Owner HYOGO COLLEGE OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com